Orchard Therapeutics Company
Orchard Therapeutics is a biotechnology company that develops and commercializes transformative ex-vivo autologous hematopoietic stem cell gene therapy. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. The company is dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.
Investors
Headquarters:
London, England, United Kingdom
Number Of Exists:
Series C
Total Funding:
$310.5M
Founded Date:
2015
Employee Number:
51-100
Investment Stage:
N/A
Last Funding Type:
Series C
Investor Type:
Company
Investors Number:
24
Technology:
Others
Funding Status:
IPO
Estimated Revenue:
$1M to $10M
Industry:
Gene Therapy